EpiPen, often chided for high price, gets first generic competitor
The drugmaker's generic had originally met with FDA rejection in early 2016, amid a national debate over EpiPen's price.
Here’s how wearables are being enlisted to study neurodegenerative diseases
Neurodegenerative diseases represent a particularly interesting area for wearables to come into play as research scientists seek to better understand disease progression.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Morning Read: Allergan makes antidepressant acquisition, an Allergan deal could give Teva big pharma status
Allergan is the center of attention in a couple of stories this morning with anti-depressant acquisition and a sale of its generics business to Teva.
Morning Read: Philips-Teva joint venture details medtech startup investments, digital health startups raise more than $2.8B in 227 deals
Teva and Philips will invest a little more than $26 million in startups over the next eight years through Sanara Ventures, digital health startups raise more than $2.8 billion.
CMS put $2.8B at risk in 2014, Teva partners with Microchips Biotech (Morning Read)
CMS failed to track subsidies paid to insurers under the PPACA putting $2.8 billion at risk for four months in 2014, Teva partnered with Microchips Biotech.
Johnson and Johnson accepts $2B offer for vascular medical device producer, Teva reaches settlement (Morning Read)
Johnson and Johnson accepted an offer from Cardinal Health to acquire vascular medical device producer, the FDA wins a lawsuit over granting companies the ability to produce a generic model of an orphan drug.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Teva snags Auspex Pharmaceutical for $3.5B, PTC acquires ColdLight (Morning Read)
TOP STORIES Teva has completed its $3.5-billion purchase of Auspex Pharmaceuticals – still keeping an eye on Mylan, though. PTC announced it has signed a definitive agreement to acquire ColdLight, a visionary in big data machine learning and predictive analytics, for approximately $105 million. LIFE SCIENCE A plant-derived compound could target cancer stem cells. […]
NIH increase moves out of committee, Teva keeps courting Mylan (Morning Read)
TOP STORIES Leaders of the House Energy and Commerce Committee have reached a deal on a draft of legislation that will speed up the approval of new drugs and treatments. Funding for the NIH — which had been a deeply disputed issue within the committee — will rise by $10 billiion over five years if […]
Mylan rejects Teva’s $40B bid, Medtronic stops distribution of pain med pump (Morning Read)
Mylan has rejected Teva's unsolicited bid. Intarcia Therapeutics raised $225 million to develop its implantable drug-delivery pump for patients with diabetes. Plus, Medtronic has agreed to halt production and distribution of its SynchroMed implantable drug pump.
PLAN B revisited: FDA rules on one-step exclusivity
By Kurt R. Karst – Even before FDA gave up an appeal of Judge Edward R. Korman’s April 2013 Judgment and Order that Teva Branded Pharmaceutical Products R&D, Inc.’s (“Teva’s”) PLAN B One-Step (levonorgestrel) Tablets, 1.5 mg (“PBOS”), be made available Over-the-Counter (“OTC”) without age or point-of-sale restrictions (see our previous post here), we were […]
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
EU regulator backs Bayer, GSK drugs, knocks back Novartis, Teva
LONDON (Reuters) – European drugs regulators gave their backing on Friday for marketing approval to be granted for Bayer’s drug Adempas, designed to treat pulmonary hypertension, and for GlaxoSmithKline’s diabetes medicine Eperzan. The regulator also backed a new drug from Dainippon Sumitomo Pharma called Latuda, for the treatment of schizophrenia, and Bemfola, a new biosimilar […]
Teva offer for NuPathe lines up bidding war with Endo Health Solutions
Less than one month after NuPathe’s (Nasdaq: PATH) board approved an acquisition offer by Endo Health Solutions, (Nasdaq: ENDP) the specialty pharmaceutical company has unexpectedly found itself at the center of what could be a bidding war after receiving another offer in a surprising development in life science industry news. Big pharma company Teva (NYSE: […]
Teva is looking for a few good entrepreneurs for a global drug launch platform
Generic pharmaceuticals manufacturer Teva Pharmaceuticals (NYSE: TEVA) wants to develop a platform to launch drugs globally and it’s calling on entrepreneurs to design one as part of the first Philly Enterprise Hackathon. The Greater Philadelphia Alliance for Capital and Technologies or PACT is behind the competition as well as other businesses such as law firm […]
Counterfeit ADHD drug Adderall prompts FDA warning
A counterfeit version of a drug to treat attention-deficit/hyperactivity disorder, or ADHD, is being sold online according to U.S. regulators amidst a shortage of the drug. The counterfeit drug, a version of Adderall produced by Teva Pharmaceuticals (NASDAQ:TEVA), has its U.S. headquarters in North Wales, Pennsylvania. Tests by the U.S. Food and Drug Administration reveal […]
Teva, Ferring boost Antares Pharma product sales
Antares Pharma product sales soared 41 percent in the first nine months of 2011 to $5.8 million, helped in part by customers Teva (NASDAQ: TEVA) and Ferring Pharmaceutical. The Ewing, New Jersey company focuses on needle-free self-injection pharmaceutical products and topical gel-based medicines and partners with larger companies such as Teva and Watson Pharmaceuticals (NYSE: […]